Track Your Prescribed Tirzepatide with Pinnacle Pulse

Tirzepatide acts on two receptors, GIP and GLP-1. Your log only has to handle one thing, and it’s far less glamorous: what happened, and on which day.

Sounds trivial. Then the pharmacy hands you a different pen than last time, the holidays scramble your routine, and by the next appointment you’re piecing six weeks together from text messages and a calendar you only half kept. Pinnacle Pulse holds your entries, sites, symptoms and refill notes on one private timeline, so the person who prescribed tirzepatide gets facts. What you take, and when, is their call. We stay out of it.

Start your private log

Regulatory and anti-doping status · Status as of 16 October 2026

  • EU: Authorized in the EU as a prescription-only medicine for specific indications.
  • United States: FDA-approved, prescription-only, for specific indications. On 1 May 2026 FDA proposed in the Federal Register not to include tirzepatide on the 503B bulks list used by outsourcing facilities; no final decision had been published by 16 October 2026. FDA has also warned about fraudulent compounded tirzepatide and products sold “for research purposes”.
  • Sport: Not prohibited. On WADA’s 2027 Monitoring Program; WADA kept the status of GLP-1 receptor agonists unchanged for 2027.
  • Use: Use only as prescribed and supervised by your physician.

Sources (checked 16 October 2026): WADA 2027 List announcement · Federal Register, 1 May 2026 · FDA on unapproved GLP-1 drugs · EMA medicines database

Four things worth writing down

  • When each entry happened. The app stamps the time; fix it if you log late.
  • The amount and unit, copied from your prescription label. No defaults. The app won’t offer you a number, ever.
  • The site. You and your care team pick the spots; the log remembers which one you used last, because by week nine nobody does.
  • Everything else, really. Refill dates, a missed entry and the reason for it, the evening you felt off, the question you want to ask next time.

Refills and the dull logistics

A lot of treatment hiccups turn out to be logistics. A refill that came late. A pen that looked different. A trip where the routine slipped by a couple of days. Write those down as plain notes. Pharmacists ask about exactly this kind of thing when something looks off, and in three weeks you won’t remember any of it.

If you compete

Tirzepatide isn’t on the WADA Prohibited List. It is on WADA’s Monitoring Program for 2027, though, which means accredited labs keep an eye on it, and WADA has said it is running studies in athletes before deciding anything further. If you’re in a testing pool, keep your prescription paperwork tidy and check Global DRO or your national anti-doping organization each time a new List is published. A dated log with your prescriber’s name in it won’t hurt.

The doctor’s copy

Export a dated record of your entries, sites, check-ins and notes. There’s no interpretation layered on top. Your doctor gets what happened, in order, and can draw their own lines.

The rest of your week

Sleep and HRV from a supported band, daily check-ins and training sessions all share the same timeline. Trend views show the averages and direction of what you logged. They don’t estimate what tirzepatide is doing, and we have no plans to make them.

Primary sources

  • Current US labeling for tirzepatide products on DailyMed: search DailyMed
  • EU product information from the European Medicines Agency: search EMA medicines
  • FDA on unapproved, compounded and “research use” GLP-1 products, including tirzepatide: fda.gov
  • Zeng et al., Frontiers in Endocrinology 2023. Meta-analysis of nine randomized trials looking at pancreatitis and gallbladder or biliary events: PubMed 37908750
  • Safwan et al., Annals of Saudi Medicine 2025. Gastrointestinal adverse events with semaglutide and tirzepatide versus placebo: PubMed 40189856
  • WADA’s announcement of the 2027 List, including its note on GLP-1 receptor agonists: wada-ama.org

Background and regulatory detail: /research/tirzepatide.

Not on this page

Brand names. Weight figures. Titration advice. Comparisons with other GLP-1 medicines. Referrals to anyone who’ll write you a prescription. None of it belongs on a tracker’s website, so you won’t find it here.

Where your data lives

The trend engine runs on your phone. Nobody is buying your data from us, because we don’t sell it, and the app ships without ad or analytics SDKs. Whatever syncs is encrypted on the way to our servers and while it’s stored there. Deleting an entry, or the whole account, is in Settings → Privacy.

FAQ

What is tirzepatide’s regulatory status?

It’s a prescription-only medicine in the EU and the US, approved for specific indications. Use it only as prescribed.

Will the app suggest when to move to a different amount?

No. Changes to your treatment are your prescriber’s decision. The app only stores what you enter.

Is tirzepatide banned for athletes?

Not as of the 2027 List. It’s on WADA’s Monitoring Program, so labs track it, and WADA has said it will revisit the question once its athlete studies report.

Can I log refills and missed entries?

Yes. Add them as notes on the timeline, where they stay searchable.

Can I export my log for appointments?

Yes, as a dated record of entries, sites, check-ins and notes.

Pinnacle Pulse is a general self-tracking and visualization app. It is not a medical device and does not provide medical advice, diagnosis, treatment or dosing recommendations. Trend views are illustrative and based only on data you log. Listing a substance is not a recommendation to use it.

Last updated: 16 October 2026.